Bolt Biotherapeutics, Inc.
BOLT
$4.28
$0.081.79%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -98.96% | 15.26% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -98.96% | 15.26% | |||
| Cost of Revenue | -8.04% | -23.67% | |||
| Gross Profit | -83.32% | 43.01% | |||
| SG&A Expenses | -10.23% | -6.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.90% | -17.90% | |||
| Operating Income | -35.61% | 27.24% | |||
| Income Before Tax | -9.24% | 7.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.24% | 7.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.24% | 7.18% | |||
| EBIT | -35.61% | 27.24% | |||
| EBITDA | -38.28% | 27.83% | |||
| EPS Basic | -12.29% | -3.15% | |||
| Normalized Basic EPS | -44.55% | 19.87% | |||
| EPS Diluted | -12.29% | -3.15% | |||
| Normalized Diluted EPS | -44.55% | 19.87% | |||
| Average Basic Shares Outstanding | -2.71% | -10.01% | |||
| Average Diluted Shares Outstanding | -2.71% | -10.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||